Vir Biotechnology, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Vir Biotechnology, Inc. (VIR) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $982.49 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $982.49M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $812.76M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $765.28M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $796.10M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $982.49M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $812.76M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $765.28M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $796.10M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $947.47M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.04B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.15B 10-K · filed 2026-02-23 |
| 2024-09-30 | $1.24B 10-Q · filed 2024-11-04 |
| 2024-06-30 | $1.43B 10-Q · filed 2024-11-04 |
| 2024-03-31 | $1.55B 10-Q · filed 2024-08-01 |
| 2023-12-31 | $1.59B 10-K · filed 2026-02-23 |
| 2023-09-30 | $1.68B 10-Q · filed 2024-11-04 |
| 2023-06-30 | $1.81B 10-Q · filed 2024-11-04 |
| 2023-03-31 | $1.97B 10-Q · filed 2024-08-01 |
| 2022-12-31 | $2.08B 10-K · filed 2026-02-23 |
| 2022-09-30 | $2.15B 10-Q · filed 2023-11-03 |
| 2022-06-30 | $1.95B 10-Q · filed 2023-11-03 |
| 2022-03-31 | $2.00B 10-Q · filed 2023-08-04 |
| 2021-12-31 | $1.43B 10-K · filed 2025-02-27 |
| 2020-12-31 | $716.85M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |